Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 36

1.
2.

Association of subarachnoid hemorrhage and phentermine usage: Coincidence, not causation.

Hendricks EJ, Rothman RB, Bryman DA, Schmidt SL.

J Am Pharm Assoc (2003). 2015 Mar-Apr;55(2):122, 124. doi: 10.1331/JAPhA.2015.14263. No abstract available.

PMID:
25616199
3.

Phentermine therapy for obesity does not elevate blood pressure.

Hendricks EJ, Rothman RB.

Diabetes Obes Metab. 2011 Oct;13(10):963-4. doi: 10.1111/j.1463-1326.2011.01435.x. No abstract available.

PMID:
21896124
4.

RE: Pulmonary hypertension associated with use of phentermine?

Hendricks EJ, Rothman RB.

Yonsei Med J. 2011 Sep;52(5):869-70. doi: 10.3349/ymj.2011.52.5.869. No abstract available.

5.

Phentermine cardiovascular safety II: response to Yosefy Int J Cardiol. 2009 Epub Mar 19.

Rothman RB, Hendricks EJ.

Int J Cardiol. 2010 Nov 19;145(2):391-392. doi: 10.1016/j.ijcard.2010.02.060. Epub 2010 Mar 6.

PMID:
20207432
6.

Phentermine cardiovascular safety.

Rothman RB, Hendricks EJ.

Am J Emerg Med. 2009 Oct;27(8):1010-3. doi: 10.1016/j.ajem.2009.07.014. No abstract available.

PMID:
19857423
7.

Treatment of obesity with "combination" pharmacotherapy.

Rothman RB.

Am J Ther. 2010 Nov-Dec;17(6):596-603. doi: 10.1097/MJT.0b013e31818e30da.

PMID:
19352140
8.

How physician obesity specialists use drugs to treat obesity.

Hendricks EJ, Rothman RB, Greenway FL.

Obesity (Silver Spring). 2009 Sep;17(9):1730-5. doi: 10.1038/oby.2009.69. Epub 2009 Mar 19.

9.

Phentermine cardiovascular safety. In response to Yosefy C, Berman M, Beeri R. Cusp tear in bicuspid aortic valve possibly caused by phentermine. International journal of cardiology 2006;106:262-3.

Rothman RB, Hendricks EJ.

Int J Cardiol. 2010 Oct 8;144(2):241-2; author reply 242-3. doi: 10.1016/j.ijcard.2008.12.205. Epub 2009 Feb 1. No abstract available.

PMID:
19189876
10.

Appetite suppressants, cardiac valve disease and combination pharmacotherapy.

Rothman RB, Baumann MH.

Am J Ther. 2009 Jul-Aug;16(4):354-64. doi: 10.1097/MJT.0b013e31817fde95. Review.

11.

Dopamine/serotonin releasers as medications for stimulant addictions.

Rothman RB, Blough BE, Baumann MH.

Prog Brain Res. 2008;172:385-406. doi: 10.1016/S0079-6123(08)00919-9. Review.

PMID:
18772043
12.

Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease.

Zolkowska D, Rothman RB, Baumann MH.

J Pharmacol Exp Ther. 2006 Aug;318(2):604-10. Epub 2006 Apr 27.

13.

Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan.

Halladay AK, Wagner GC, Sekowski A, Rothman RB, Baumann MH, Fisher H.

Synapse. 2006 Apr;59(5):277-89.

PMID:
16416445
14.

Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis.

Alexander M, Rothman RB, Baumann MH, Endres CJ, Brasić JR, Wong DF.

Synapse. 2005 May;56(2):94-9.

PMID:
15729739
16.

Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin.

Rothman RB, Baumann MH, Dersch CM, Romero DV, Rice KC, Carroll FI, Partilla JS.

Synapse. 2001 Jan;39(1):32-41.

PMID:
11071707
17.

Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens: therapeutic implications.

Baumann MH, Ayestas MA, Dersch CM, Brockington A, Rice KC, Rothman RB.

Synapse. 2000 May;36(2):102-13.

PMID:
10767057
18.

Chronic treatment with phentermine combined with fenfluramine lowers plasma serotonin.

Rothman RB, Redmon JB, Raatz SK, Kwong CA, Swanson JE, Bantle JP.

Am J Cardiol. 2000 Apr 1;85(7):913-5, A10. Erratum in: Am J Cardiol 2000 Jun 15;85(12):1511.

PMID:
10758942
19.

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications.

Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL.

Circulation. 2000 Dec 5;102(23):2836-41.

PMID:
11104741
20.

Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension.

Rothman RB, Ayestas MA, Dersch CM, Baumann MH.

Circulation. 1999 Aug 24;100(8):869-75.

PMID:
10458725

Supplemental Content

Loading ...
Support Center